STOCK TITAN

Dianthus Therapeutics, Inc. - DNTH STOCK NEWS

Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.

Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company dedicated to the design and delivery of novel monoclonal antibodies with enhanced selectivity and potency. The company's primary focus is on developing next-generation complement therapeutics aimed at treating severe autoimmune and inflammatory diseases. With a seasoned team of biotech and pharma executives, Dianthus Therapeutics is at the forefront of innovation in complement therapies.

The company's flagship product, DNTH103, is an investigational active C1s inhibitor. This potent monoclonal antibody is engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein. Enhanced with YTE half-life extension technology, DNTH103 is designed for convenient subcutaneous, self-administered injections dosed as infrequently as once every two weeks. This selective inhibition promises to lower patient risk of infection while maintaining immune activity of the lectin and alternative pathways.

One of the latest milestones for Dianthus Therapeutics is the initiation of the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis (gMG). The trial, which began following FDA clearance, aims to evaluate the safety, tolerability, and efficacy of DNTH103. The randomized, double-blind, placebo-controlled study includes up to 60 patients who are acetylcholine receptor (AchR) antibody positive. Following an initial loading dose, DNTH103 is administered every two weeks via subcutaneous injection for 12 weeks, with an option for a 52-week open-label extension. The primary endpoint is safety and tolerability, with secondary endpoints including assessments using the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores. Initial top-line results are anticipated in the second half of 2025.

Dianthus Therapeutics is also making strides in other areas. The company plans to initiate additional Phase 2 trials in 2024 for other neuromuscular indications such as Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. The aim is to build a comprehensive neuromuscular franchise around DNTH103, leveraging its unique capabilities and potential as a best-in-class treatment option.

Financially, 2023 was a transformative year for Dianthus, marked by its transition to a public company and the successful completion of a $230 million PIPE financing. This financial runway extends into the second half of 2027, providing the company with the resources needed to achieve key milestones and data readouts in the coming years.

For more information, visit Dianthus Therapeutics and follow them on LinkedIn.

Disclaimer: Certain statements in this description may constitute forward-looking statements within the meaning of federal securities laws. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

Rhea-AI Summary

Dianthus Therapeutics announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology, held in Helsinki from June 29 to July 2, 2024. DNTH103 is an investigational inhibitor targeting the active form of C1s, being evaluated for the treatment of severe neuromuscular conditions like generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy. The presentations will showcase preclinical and in vitro data, highlighting DNTH103's potential advantages over existing treatments. The CEO emphasized DNTH103's potential for safer, more convenient administration with consistent symptom control and fewer risks compared to current therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary

Dianthus Therapeutics has received FDA clearance to start a Phase 2 trial for DNTH103 in treating Multifocal Motor Neuropathy (MMN). This trial, named the MoMeNtum study, will assess the safety, tolerability, and efficacy of DNTH103 in 36 patients globally. The trial will follow a randomized, double-blind, placebo-controlled design, with patients receiving subcutaneous injections every two weeks for 17 weeks, followed by a 52-week open-label extension. Top-line results are expected in the second half of 2026. DNTH103, a potent C1s inhibitor, aims to offer a more convenient treatment option than current therapies. Dianthus is also building a neuromuscular franchise with planned trials in generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
-
Rhea-AI Summary

Dianthus Therapeutics, a biotechnology company focused on antibody complement therapeutics for autoimmune diseases, will participate in the Jefferies Global Healthcare Conference.

The company’s CEO, Marino Garcia, will present a corporate overview on June 6, 2024, at 1:30 p.m. ET in New York.

A live webcast of the presentation will be accessible via the Investors section of Dianthus Therapeutics' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
Rhea-AI Summary

Dianthus Therapeutics, a clinical-stage biotech company, reported financial results for Q1 2024, highlighting the initiation of Phase 2 MaGic trial for gMG using DNTH103, with ongoing trials in MMN and CIDP. The company raised $377 million in cash through successful financing, projecting runway till 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
-
Rhea-AI Summary

Dianthus Therapeutics, a clinical-stage biotechnology company, will participate in the Bank of America Securities 2024 Health Care Conference. The CEO will present a corporate overview, focusing on antibody complement therapeutics for severe autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
conferences
-
Rhea-AI Summary

Dianthus Therapeutics, Inc. announced the granting of equity awards to two new non-executive employees as inducements for their employment. The awards comprised non-qualified stock options for a total of 52,000 shares, with a 10-year term and an exercise price of $22.53 per share. The options vest gradually over a 3-year period, subject to specific conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
none
Rhea-AI Summary
Dianthus Therapeutics, Inc. (DNTH) announces an oral presentation for DNTH103 at the American Academy of Neurology Annual Meeting. DNTH103 is a classical pathway inhibitor being evaluated for severe autoimmune diseases. The presentation will focus on preclinical and in vitro data showcasing DNTH103's safety profile and effectiveness for neuromuscular conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.11%
Tags
none
-
Rhea-AI Summary
Dianthus Therapeutics, Inc. granted equity awards to six newly-hired employees as material inducements. The grants include non-qualified stock options to purchase 126,000 shares at $29.72 per share, vesting over 37 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
none
-
Rhea-AI Summary
Dianthus Therapeutics, Inc. reported financial results for Q4 and full year 2023, highlighting a successful PIPE financing of $230 million in January 2024. The company aims to build a neuromuscular franchise around DNTH103, a potent C1s inhibitor, with Phase 2 MaGic trial in gMG ongoing and planned trials in MMN and CIDP. The company's cash position stands at $389 million, providing runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.32%
Tags
Rhea-AI Summary
Dianthus Therapeutics, Inc. (DNTH) granted an equity award to a newly-hired employee, consisting of a non-qualified stock option to purchase 30,000 shares with a 10-year term and an exercise price of $25.75 per share. The option vests over 3 years, subject to specific conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none

FAQ

What is Dianthus Therapeutics, Inc.?

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation monoclonal antibodies for severe autoimmune and inflammatory diseases.

What is DNTH103?

DNTH103 is an investigational, potent monoclonal antibody engineered to selectively target the active C1s protein in the classical complement pathway, designed for subcutaneous self-administration.

What is the Phase 2 MaGic trial?

The Phase 2 MaGic trial is a study initiated to evaluate the safety, tolerability, and efficacy of DNTH103 in patients with generalized Myasthenia Gravis (gMG).

What are the primary and secondary endpoints of the MaGic trial?

The primary endpoint is safety and tolerability, while secondary endpoints include assessments using the Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores.

What is the duration of the MaGic trial?

The subcutaneous treatment duration is initially 12 weeks, with an option for a 52-week open-label extension.

What are the anticipated outcomes of the MaGic trial?

Initial top-line results from the MaGic trial are anticipated to be available in the second half of 2025.

What financial milestones did Dianthus achieve in 2023?

In 2023, Dianthus transitioned to a public company and completed a $230 million PIPE financing, extending its financial runway into the second half of 2027.

What are Dianthus Therapeutics' future plans for DNTH103?

Dianthus plans to initiate additional Phase 2 trials in 2024 for neuromuscular indications such as Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.

How can I learn more about Dianthus Therapeutics?

For more information, visit Dianthus Therapeutics' website at www.dianthustx.com and follow them on LinkedIn.

Who should be contacted for more information?

For more information, contact Jennifer Davis Ruff at Dianthus Therapeutics (jdavisruff@dianthustx.com).

Dianthus Therapeutics, Inc.

Nasdaq:DNTH

DNTH Rankings

DNTH Stock Data

821.20M
29.35M
8.84%
89.13%
6.7%
Biotechnology
Healthcare
Link
United States of America
CAMBRIDGE